R. Eguia

Receptor binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2

This study shows that RBD antibodies contribute more to SARS-CoV-2 neutralization when target cells have high ACE2 expression, highlighting ACE2 levels as a critical experimental factor.

A human coronavirus evolves antigenically to escape antibody immunity

This study shows that human coronavirus 229E evolves antigenically to escape antibody immunity, suggesting the need for periodic vaccine updates.

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.

Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays

This paper provides a protocol for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein to measure neutralizing antibody activity in a luciferase-based assay.

Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin

The paper maps how amino-acid mutations in influenza's hemagglutinin affect neutralization by polyclonal human sera, showing individual variation in escape mutations not observed in ferrets.

Comprehensive mapping of avian influenza polymerase adaptation to the human host

This study maps amino-acid mutations in avian influenza PB2 polymerase that enhance growth in human cells, identifying new adaptive mutations and their evolutionary constraints.